Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/11516
Title: Pharmacodynamic analysis of tumour perfusion assessed by 15O-water-PET imaging during treatment with sunitinib malate in patients with advanced malignancies.
Authors: Scott, Andrew M;Mitchell, Paul L R;O'Keefe, Graeme J;Saunder, Timothy;Hicks, Rodney J;Poon, Aurora M T;Baum, Charles;Brega, Nicoletta;McCarthy, Timothy J;Toner, Guy C
Affiliation: Centre for PET, Ludwig Institute for Cancer Research and Ludwig Oncology Unit, Austin Hospital, Studley Road, Heidelberg, Victoria, 3084, Australia
andrew.scott@ludwig.edu.au.
Issue Date: 9-Jun-2012
Citation: Ejnmmi Research 2012; 2(1): 31
Abstract: We evaluated pharmacodynamic changes in tumour perfusion using positron emission tomography (PET) imaging with 15O-water to assess biological response to sunitinib, a multitargeted tyrosine kinase inhibitor.Patients with advanced malignancies received sunitinib 50 mg/day orally, once daily for 4 weeks on treatment, followed by 2 weeks off treatment, in repeated 6-week cycles. Quantitative measurement of tumour perfusion was assessed using 15O-water-PET at baseline and after 2 weeks of treatment. At least one reference tumour lesion was included in the fields of view and assessed at both time points. Patients also underwent 18 F-fluorodeoxyglucose (FDG)-PET imaging at baseline and after 2 and 4 weeks of treatment. Radiological response of the reference tumour lesion and overall radiological response were assessed at week 12. Serum pharmacokinetic and biomarker analyses were also performed.Data were available for seven patients. Compared with baseline, all patients experienced a decrease in reference tumour blood flow ranging from 20 % to 85 % and also a reduction in the FDG standard uptake value ranging from 29 % to 67 %. Six patients experienced a partial metabolic response based on FDG-PET criteria. Four patients had stable disease defined by radiological response (Response Evaluation Criteria in Solid Tumors) lasting between 4 and 12 cycles. An association between perfusion change and clinical benefit, and biomarker levels including vascular endothelial growth factor was observed.Administering sunitinib to patients with advanced malignancies is associated with early biological responses, including decreased blood flow in secondary tumour deposits.
Internal ID Number: 22682364
URI: http://ahro.austin.org.au/austinjspui/handle/1/11516
DOI: 10.1186/2191-219X-2-31
URL: http://www.ncbi.nlm.nih.gov/pubmed/22682364
Type: Journal Article
Appears in Collections:Journal articles

Files in This Item:
File Description SizeFormat 
22682364.pdf838.73 kBAdobe PDFThumbnail
View/Open


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.